A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression

Trial Profile

A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Busulfan (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Autologous stem cell therapy
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms BuMelMCRN001
  • Most Recent Events

    • 05 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2022.
    • 20 Sep 2017 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
    • 20 Sep 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top